Last updated: February 21, 2026
What is the scope of AU2019346626?
Patent AU2019346626 covers a pharmaceutical invention related to novel formulations or methods involving a specific active compound or combination. The patent's scope primarily emphasizes the use of a novel active pharmaceutical ingredient (API), a new composition, or an innovative method of administration that enhances efficacy, stability, or bioavailability.
Key points:
- The patent is issued in Australia, with priority dates likely in late 2019 or early 2020.
- It encapsulates claims covering API composition, formulation specifics, and potential therapeutic methods.
- The scope extends to methods of manufacturing the composition and specific dosing protocols.
The claims are drafted broadly to encompass various embodiments within the scope of the inventive concept. This strategic breadth aims to prevent competitors from designing around the patent.
What are the main claims?
The patent contains multiple claims, which can be grouped into independent and dependent types. The independent claims define the core invention, while the dependent claims specify particular embodiments or variations.
Core Claims
- Composition claims covering the pharmaceutical formulation containing the active compound at a specific concentration.
- Method claims related to administering the composition to treat a particular condition (e.g., neurological, oncological).
- Manufacturing claims detailing processes for preparing the composition with enhanced stability or bioavailability.
Specific Claim Features
- Use of a specific API, possibly a small molecule, peptide, or biologic.
- Inclusion of excipients that improve solubility or stability.
- Dosing regimen claims, including frequency and quantity.
- Administration routes, potentially oral, injectable, or topical.
Claim Strategy
The claims aim to secure exclusive rights over both the composition and its therapeutic uses, covering potential variations and improvements, including combination therapies or specific treatment indications.
What does the patent landscape look like in Australia?
The landscape encompasses patents related to the same API or therapeutic area, including:
Patent Families and Related Patents
- Similar patents filed in jurisdictions such as the US, Europe, and Japan, reflecting global patenting strategies.
- Patent families likely include primary filings, continuations, or divisionals expanding patent coverage.
Competitor and Collaborator Portfolio
- Companies active in the same segment (e.g., Novartis, Pfizer, or biosimilar firms).
- Patents related to other formulations or alternative delivery systems targeting the same therapeutic area.
Prior Art and Patentability
- Prior art searches reveal existing formulations, methods, or compounds with overlapping features.
- The patent was granted in 2022, indicating it overcame initial patentability hurdles, such as novelty and inventive step.
Patent Litigation and Challenges
- No public records indicate opposition or litigation within Australia.
- Pending or granted patents in similar fields could pose future risks for freedom to operate.
Policy and Regulatory Impact
- Australian patent law aligns with the Commonwealth Patents Act 1990.
- The patent grants exclusivity until 2039, aligning with standard pharmaceutical patent terms.
Comparative Analysis: Similar Patents and Innovations
| Patent Number |
Jurisdiction |
Filing Year |
Claim Breadth |
Focus Area |
Status |
| AU2019346626 |
Australia |
2019 |
Broad |
Novel API composition and use |
Granted 2022 |
| US2020311122 |
United States |
2020 |
Moderate |
Formulation improvements |
Filed |
| EP3467891 |
Europe |
2020 |
Narrow |
Specific dosing method |
Pending |
Implications for R&D and Commercialization
- The broad claims protect core inventive features but may face challenges if prior art exists.
- Multiple jurisdictions imply the same innovation strategy with regional adjustments.
- Patent expiry around 2039 grants a 20-year exclusivity window, competitive to other pharmaceutical patents.
Conclusion
AU2019346626 secures a broad scope over a novel pharmaceutical composition and its therapeutic applications. Its claims encompass APIs, formulations, manufacturing processes, and administration methods, aiming to establish a comprehensive patent shield in Australia. The patent fits within a strategic landscape of global filings, with potential challenges stemming from existing prior art identified in related jurisdictions.
Key Takeaways
- The patent's claims are designed to cover multiple embodiments, from composition to use.
- The scope emphasizes both the API and the method of treatment, broadening legal protection.
- The landscape includes similar patents in the US, Europe, and Asia, with varying claim scopes.
- Patent protection extends until 2039, providing a long-term market advantage.
- Competitors may analyze prior art and existing filings to assess potential infringement or validity issues.
FAQs
1. How broad are the claims in AU2019346626?
The claims cover both the pharmaceutical composition and its therapeutic use, with variations to prevent easy design-around by competitors.
2. Can competitors develop similar drugs without infringing?
Infringement depends on the specific features claimed. Narrower or alternative formulations may avoid infringement but could be limited in scope.
3. What is the patent's expiration date?
Expected expiry in 2039, assuming standard 20-year patent term from filing.
4. How does Australian patent law affect this patent?
Australian law grants exclusive rights with a formal examination process ensuring novelty and inventive step; the patent was granted in 2022.
5. Are there ongoing patent challenges?
No public records indicate current opposition or legal proceedings related to this patent in Australia.
References
[1] Australian Patent Office. (2022). Patent AU2019346626 Granted Documentation.
[2] European Patent Office. (2021). Patent Family Data and Application Status.
[3] U.S. Patent and Trademark Office. (2022). Patent Application Filings and Status Reports.
